By establishing a receptor-mediated mechanism of statin myotoxicity, this study opens the door to genotype-informed statin prescribing, rational engineering of “RyR1-silent” lipid-lowering agents, and improved long-term adherence in patients with endocrine and metabolic disorders. Here, RYR1 is linked to metabolic disease.